International AIDS Conference VIII: Protease inhibitors.


International AIDS Conference VIII: Protease inhibitors.

Seattle Treatment Education Project: STEP Perspective - Volume 4, Number 3 - October 1992
Lori Panther, M.D.

Several laboratory studies were presented of a promising HIV inhibitor categorized under the class of protease inhibitors. Protease inhibitors prevent maturation of the HIV virus, so infectious viruses are not produced and theoretically the HIV infection is prevented from progressing.

An effective form of protease inhibitor, Abbott 80987, was found to be active against HIV-infected cells in the laboratory, and oral absorption was good as measured in laboratory animals (Norbeck, USA, ThA1507). Another protease inhibitor, U-75875 (Upjohn) was found to be effective in suppression of HIV replication in chronically infected cells called macrophages; these cells serve as a reservoir of HIV (Perno, USA, ThA15604). However, one group found certain laboratory-adapted strains of HIV which were resistant to protease inhibitors (Patterson, USA, ThA1506).

Preliminary findings on new agents. Several new compounds with anti-HIV activity tested only in the laboratory were reported. Quinobene, a sulfonated dye compound, was found to be effective against HIV-1 and HIV-2 as well as AZT-resistant isolates (Bader, USA, PoA2297). BRL 47923 is a nucleoside RT inhibitor found to have in vitro anti-HIV activity (Kenig,UK,PoA2311). A sulfated derivative of a drug called chitosan has been found to have similar properties (Kornilaveva, Russia, PoA2312). Another non- nucleoside RT inhibitor from a class of drugs called thiazolo-iso- indolinones (the compound tested was numbered BM21.1298) was noted to be effective against HIV-1 only (Maas, Germany, PoA2314). An in vitro study of the immunotherapeutic agent RFT5-dgA, which is selectively toxic for HIV-infected CD4 cells, showed suppression of viral production in HIV-infected cell culture (Bell, USA, PoB3438).
9210
STEP4324

Always watch for outdated information. This article first appeard in 1992. This material is designed to support, not replace, the relationship that exists between you and your doctor.

Copyright © 1992 - Seattle Treatment Education Project (STEP) - All rights reserved. Noncommercial reproduction is encouraged. STEP is published four times a year by the Seattle Treatment Education Project, 127 Broadway East, 3rd Floor, Seattle, WA 98102.    Email: step100@aol.com  STEP web page

This information is designed to support, not replace, the relationship that exists between you and your doctor.
©1992. AEGIS.